TNGX
Tango Therapeutics, Inc.stockNASDAQ
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today's targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango's programs is an increasingly sophisticated ability to util
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 24.85 | 2026-11-12 | -11.91% | 4.221 |
| 1M | 23.53 | 2026-10-19 | -6.97% | 2.280 |
| 3M | 25.20 | 2026-08-19 | -13.13% | 2.064 |
| 6M | 20.30 | 2026-05-19 | +7.83% | 2.215 |
| 1Y | 8.29 | 2025-11-19 | +164.21% | 1.673 |
| 2Y | 3.85 | 2024-11-19 | +468.57% | — |
| 5Y | 11.97 | 2021-11-19 | +82.87% | 1.345 |
Tango Therapeutics, Inc. (NASDAQ:TNGX) stock price today is $21.89, and today's volume is 2,746,148. TNGX is down 0.995% today. The 30 day average volume is 4.03M. TNGX market cap is $3.71B with 169.46M shares outstanding.